World Library  
Flag as Inappropriate
Email this Article

Idiopathic pulmonary haemosiderosis

Article Id: WHEBN0005020349
Reproduction Date:

Title: Idiopathic pulmonary haemosiderosis  
Author: World Heritage Encyclopedia
Language: English
Subject: Alveolar lung disease, List of diseases (I), Respiratory bronchiolitis interstitial lung disease, Nasal septal hematoma, Silo-filler's disease
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Idiopathic pulmonary haemosiderosis

Idiopathic pulmonary hemosiderosis
Classification and external resources
ICD-9-CM 516.1
OMIM 178550
DiseasesDB 29717

Idiopathic pulmonary haemosiderosis (or idiopathic pulmonary hemosiderosis; IPH) is a lung disease of unknown cause that is characterized by alveolar capillary bleeding and accumulation of haemosiderin in the lungs. It is rare, with an incidence between 0.24[1] and 1.23[2] cases per million people.

Contents

  • History 1
  • Pathophysiology 2
    • Related or similar conditions 2.1
  • Diagnosis 3
  • Treatment 4
  • Prognosis 5
  • References 6
  • External links 7

History

The condition was first described as "brown lung induration" by Rudolf Virchow in 1864 in patients after their death. Wilhelm Ceelen later correlated his findings to the clinical symptoms of two children who died of IPH in 1931.[3] The first living patient was diagnosed by Jan Waldenström in 1944.[4] It has been given several names, including:

  • Haemosiderin accumulation
  • Pulmonary haemosiderosis
  • Brown induration of lung
  • Essential brown induration of lung
  • Ceelen-Gellerstedt syndrome (after physicians Wilhelm Ceelen and Nils Gellerstedt)[5]

Pathophysiology

Being idiopathic, IPH by definition has an unknown cause. It is thought to be an immune-mediated disease.[6][7] The lung bleeding causes accumulation of iron, which in itself causes additional lung damage. Meanwhile, there is insufficient iron for inclusion into the haemoglobin molecules inside red blood cells which carry oxygen to body tissues for cellular respiration.

Idiopathic pulmonary haemosiderosis can occur either as a primary lung disorder or as the sequela to other pulmonary, cardiovascular or immune system disorder.

A distinct subset of patients with pulmonary hemosiderosis has hypersensitivity to cow's milk which result in formation of IgG antibodies against basement membrane. This is called Heiner syndrome. Mechanism of haemorrhage is similar as in Goodpasture syndrome.

Related or similar conditions

There are many pulmonary problems that may seem to mimic haemosiderosis but do not necessarily include the deposits of iron into the lung. The deposition of iron in the lungs, occurring in the form of haemosiderin, is the defining characteristic of this illness. These other conditions may occur separately or together with haemosiderosis.

  • Pulmonary Fibrosis
  • Adult Respiratory Distress Syndrome (ARDS)
  • Immune Complex Disease
  • intra-alveolar bleeding

Diagnosis

Clinically, IPH manifests as a triad of haemoptysis, diffuse parenchymal infiltrates on chest radiographs, and iron deficiency anaemia. It is diagnosed at an average age of 4.5 plus or minus 3.5 years,[8] and it is twice as common in females.[8] The clinical course of IPH is exceedingly variable, and most of the patients continue to have episodes of pulmonary haemorrhage despite therapy. Death may occur suddenly from acute pulmonary haemorrhage or after progressive pulmonary insufficiency resulting in chronic respiratory failure.

Treatment

Corticosteroids are the mainstay of treatment of IPH, though they are controversial and lack clear evidence in their favour.[9] They are thought to decrease the frequency of haemorrhage,[10][11][12] while other studies suggest that they do not have any effect on the course or prognosis of this disease.[6][10][13] In either case, steroid therapy has significant side effects. Small trials have investigated the use of other medications, but none has emerged as a clear standard of care. This includes immune modulators such as hydroxychloroquine,[14][15] azathioprine,[16][17] and cyclophosphamide.[18] 6-mercaptopurine as a long-term therapy may prevent pulmonary haemorrhage.[19] A 2007 scientific letter. reports preliminary success in preventing pulmonary haemorrhage with the anti-oxidant N-acetylcysteine.[20]

Prognosis

Death may occur rapidly with acute, massive pulmonary bleeding or over longer periods as the result of continued pulmonary failure and right heart failure. Historically, patients had an average survival of 2.5 years after diagnosis, but today 86% may survive beyond five years.[8]

References

  1. ^ Kjellman B, Elinder G, Garwicz S, Svan H (September 1984). "Idiopathic pulmonary haemosiderosis in Swedish children". Acta Paediatr Scand 73 (5): 584–8.  
  2. ^ Ohga, S; Takahashi, K; Miyazaki, S; Kato, H; Ueda, K (1995). "Idiopathic pulmonary haemosiderosis in Japan: 39 possible cases from a survey questionnaire". European Journal of Pediatrics (letter) 154 (12): 994–995.  
  3. ^ Ceelen, W. (1931). "Die Kreislaufstörungen der Lungen". In Henke, F.; Lubarsch, O. Handbuch der speziellen pathologischen Anatomie und Histologie (in German) 3. Berlin: Springer. p. 10. 
  4. ^ Heiner, DC (1990). "Pulmonary hemosiderosis". In Chernick, V Kendig, EL, Jr. Disorders of the respiratory tract in children. Philadelphia PA: WB Saunders. pp. 498–509. 
  5. ^ Ceelen-Gellerstedt syndrome at Who Named It?
  6. ^ a b Soergel KH, Sommers SC (1962). "Idiopathic pulmonary hemosiderosis and related syndromes". Am J Med 32: 499–511.  
  7. ^ Gonzalez-Crussi, F, Hull, MT, Grosefeld, JL (1976). "Idiopathic pulmonary hemosiderosis: evidence of capillary basement membrane abnormality". Am Rev Respir Dis 114 (4): 689–698.  
  8. ^ a b c Saeed, Muhammad M; Woo, Marlyn S; MacLaughlin, Eithne F; Margetis, Monique F; Keens, Thomas G (September 1999). "Prognosis in Pediatric Idiopathic Pulmonary Hemosiderosis".  
  9. ^ Sethi, GR; Singhal, KK (Oct 2008). "Pulmonary diseases and corticosteroids". Indian Journal of Pediatrics 75 (10): 1045–56.  
  10. ^ a b Matsaniotis N, Karpouzas J, Apostolopoulou E, et al. (1968). "Idiopathic pulmonary hemosiderosis in children". Arch Dis Child 43 (229): 307–309.  
  11. ^ Beckerman RC, Taussig LM, Pinnas JL (June 1979). "Familial idiopathic pulmonary hemosiderosis". Am. J. Dis. Child. 133 (6): 609–11.  
  12. ^ Gilman PA, Zinkham WH (1969). "Severe idiopathic pulmonary hemosiderosis in the absence of clinical or radiologic evidence of pulmonary disease". J Pediatr 75 (1): 118–121.  
  13. ^ Boat, TF (1998). "Idiopathic pulmonary hemosiderosis". In Chernick, V Boat, T. Kendig’s disorders of the respiratory tract in children. Philadelphia PA: WB Saunders. pp. 628–9. 
  14. ^ Bush A, Sheppard MN, Warner JO (1992). "Chloroquine in idiopathic pulmonary hemosiderosis". Arch Dis Child 67 (5): 625–627.  
  15. ^ Zaki M, Al Saleh Q, Al Mutari G (1995). "Effectiveness of chloroquine therapy in idiopathic pulmonary hemosiderosis". Pediatric Pulmonology 20: 1206.  
  16. ^ Byrd RB, Gracey DR (1973). "Immunosuppressive treatment of idiopathic pulmonary hemosiderosis".  
  17. ^ Rossi GA, Balzano E, Battistini E (1992). "Long-term prednisone and azathioprine treatment of a patient with idiopathic pulmonary hemosiderosis". Pediatr Pulmonol 13 (3): 176–180.  
  18. ^ Colombo JR, Stolz SM (1992). "Treatment of life-threatening primary pulmonary hemosiderosis with cyclophosphamide".  
  19. ^ Luo XQ, Ke ZY, Huang LB, Guan XQ, Zhang XL, Zhu J, Zhang YC (Nov 2008). "Maintenance therapy with dose-adjusted 6-mercaptopurine in idiopathic pulmonary hemosiderosis". Pediatric Pulmonology 43 (11): 1067–71.  
  20. ^ "Idiopathic Pulmonary Haemosiderosis - World 1st Medical Treatment By Researchers At Queen Mary University London And University Of Leicester". Medical New Today. 2 June 2007. 

External links

  • Hemosiderosis at eMedicine
  • About.com article
  • Discovery.com article
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.